Ayala Pharmaceuticals, Inc. (ADXS)

Ayala Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	4.88	2.41
Cash & Short-Term Investments	4.88	2.41
Cash Growth	102.74%	-
Receivables	-	0.23
Prepaid Expenses	2.14	0.43
Other Current Assets	0.5	0.12
Total Current Assets	7.53	3.19
Property, Plant & Equipment	0.64	2.42
Goodwill	4.5	-
Other Intangible Assets	3.9	-
Long-Term Deferred Charges	-	1.95
Other Long-Term Assets	0.01	0.21
Total Assets	16.58	7.77

Liabilities

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Accounts Payable	6.08	4.08
Accrued Expenses	6.34	1.7
Current Portion of Leases	0.17	0.42
Other Current Liabilities	12.44	-
Total Current Liabilities	25.02	6.2
Long-Term Debt	8.14	-
Long-Term Leases	0.01	1.33
Other Long-Term Liabilities	7.83	1.34
Total Liabilities	41	8.87

Shareholders' Equity

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Common Stock	0.01	0
Additional Paid-In Capital	172.8	148.05
Retained Earnings	-197.23	-149.15
Shareholders' Equity	-24.42	-1.1
Total Liabilities & Equity	16.58	7.77

Additional Metrics

Fiscal Year	FY 2023	FY 2022
Period Ending	Dec 31, 2023	Dec 31, 2022
Total Debt	8.32	1.75
Net Cash (Debt)	-3.43	0.66
Net Cash Growth	-	-
Net Cash Per Share	-0.57	0.23
Filing Date Shares Outstanding	42.63	2.9
Total Common Shares Outstanding	11.9	2.9
Working Capital	-17.49	-3.01
Book Value Per Share	-2.05	-0.38
Tangible Book Value	-32.82	-1.1
Tangible Book Value Per Share	-2.76	-0.38
Machinery	0.25	0.52
Leasehold Improvements	1.11	1.11

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2023

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every year for this company.

Update frequency:

Yearly

Last checked:

Jan 31, 2026

Data Sources Report a data error